Bausch + Lomb Corporation
BLCO
Updated: 24/09/2026, 12:02:33
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
No summaries found.
- Share price
- $17.05
- Market cap
- $6.09B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Brenton L. Saunders
- Employees
- 13,000
- IPO date
- 06/05/2022
- Beta
- 0.5570000000000001
- Last dividend
- $0.00
- Day range
- $16.88 – $17.43
- 52-week range
- $13.77 – $18.92
- 1-day performance
- -1.56%
- 1-year performance
- 23.86%
- Current drawdown (1Y)
- -9.86%
- CIK
- 0001860742
- CUSIP
- 071705107
- ISIN
- CA0717051076
- Created
- 07/12/2025, 03:01:29
- Last update
- 24/09/2026, 12:02:33
Track Bausch + Lomb Corporation with an AI analyst
See which prediction-market events move BLCO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 21:32:10
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript
Seeking Alpha • STOCK • 01/06/2026, 19:44:04
Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 29/04/2026, 19:01:53
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story
The Motley Fool • STOCK • 24/03/2026, 20:24:05
Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript
Seeking Alpha • STOCK • 23/03/2026, 23:33:38
Bausch + Lomb Corporation Investigated by the Portnoy Law Firm
GlobeNewsWire • STOCK • 13/03/2026, 10:00:00
Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats
Seeking Alpha • STOCK • 19/02/2026, 15:54:45
Bausch + Lomb (BLCO) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research • STOCK • 19/02/2026, 14:01:15
Bausch + Lomb (BLCO) Lags Q4 Earnings Estimates
Zacks Investment Research • STOCK • 18/02/2026, 10:11:11
Ahead of Bausch + Lomb (BLCO) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Zacks Investment Research • STOCK • 16/02/2026, 11:16:12
BLCO or DHR: Which Is the Better Value Stock Right Now?
Zacks Investment Research • STOCK • 09/02/2026, 13:41:10